Leadership

William L. Greene, MD

Chief Executive Officer

Dr. Greene has been Iconic Therapeutics’ CEO and a Director since 2014, bringing 20 years as an operating executive, clinician, investor, and entrepreneur. He joined from MPM Capital, where he was Managing Director and an Investment Committee member, leading investments and serving on Boards of emerging biopharmaceutical and medical device companies.

Previously, Dr. Greene was a Senior Clinical Scientist and Epidemiologist at Genentech, responsible for clinical strategy, trial design and execution, and regulatory interactions in several therapeutic areas at all development stages, including leading the early clinical development of Lucentis®. Before that, he was a Resident in Internal Medicine and Diagnostic Radiology at Yale, and an Assistant Professor of Medicine at UCSF.

Dr. Greene received his B.A. from Wesleyan University and an M.D. from UCSF. He was a Robert Wood Johnson Clinical Scholar at Yale (clinical epidemiology) and a Howard Hughes Medical Institute Research Scholar at the NIH (neurobiology). He’s co-founder of and Senior Advisor to Pear Therapeutics and a long-standing advisor to the Bill and Melinda Gates Foundation, Worldmedicalguide. He’s the founding Chairman of the Board and head of the Investment Committee of the Global Health Investment Fund, the largest impact-oriented life science venture capital fund devoted to global health.

Gabriela Burian, MD, MPH

Chief Medical Officer

Dr. Burian has more than 15 years of clinical research and development experience focused on retinal disease, with extensive practice in designing, planning and executing global clinical programs. Dr. Burian joined Novartis Pharma in 2005 as Clinical Research Scientist and later held various leadership and management positions including Global Program Medical Director. She was also responsible for clinical development strategies across multiple retinal indications, including age-related macular degeneration, diabetic macular edema (DME), retinal vein occlusion (RVO) and pathologic myopia (PM). She successfully led the global (ex-U.S.) regulatory interactions and approvals of Lucentis® for DME, RVO and PM indications in more than 100 countries.

Most recently, Dr. Burian served as the Ophthalmology Early Program Leader at F. Hoffmann-La Roche, where she was responsible for establishing the translational medicine group and leading early clinical development strategy. Dr. Burian received an M.D. from Victor Babes University of Medicine and Pharmacy in Romania, and a Master’s in Public Health in epidemiology from Rollins School of Public Health at Emory University. After completing her graduate work, Dr. Burian was a Clinical Research Manager and member of the faculty in the Ophthalmology Department at Emory University.

Cynthia Porter

Head of Development Operations

Cynthia has over 30 years of clinical operations, project and portfolio management. Her experience encompasses ophthalmology, oncology, and immunology among other indications. Cynthia has various leadership positions at Roche, Genentech and AbbVie. Cynthia led the Lucentis clinical operations team through Phase 3. She has a B.S.N. from the University of Northern Colorado and an M.B.A from City University.

Julie B. Friedman

Vice President Alliance and Program Management

Julie has over 25 years of experience in the Pharma/Biotech sector.  She joined Iconic from Quark Pharmaceuticals where she was the VP of Alliance and Program Management responsible for driving and managing the R&D Portfolio and all partner relationships.

Previous to this Julie worked in both small and large Pharma/Biotech companies. She has managed programs from Lead Candidate Identification through commercial launch at Medivation, Genentech, Takeda, and Bristol-Myers Squibb, heading programs with annual budgets of $25-100 million/year. Julie co-lead the successful filing for Medivation’s Extandi® sNDA. She managed major alliances at Quark, Medivation and Genentech with Roche, Biocon, Astellas and Merk Serono. Julie has been involved in professional organizations such as the Sigma Theta Tau (Alpha Chapter) Nursing honor society, the Industry Pharmacogenomics Working Group I-PWG (as Chairman in 2002-2003), the Association of Strategic Alliance Professionals and the Bay Area Biopharma Project Management.

Starting her career as an ICU Nurse, she moved to the Public Health sector for both the US Centers for Disease Control and the Israeli Ministry of Health. Julie holds and Master of Public Health in International Public Health from Emory University and a Bachelor of Science in Nursing from Indiana University.